Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Sells $1,098,773.28 in Stock

by · The Markets Daily

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) CEO Greef Roderick De sold 46,896 shares of the firm’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the completion of the sale, the chief executive officer now owns 414,958 shares of the company’s stock, valued at $9,722,465.94. This trade represents a 10.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $26.61 on Friday. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $28.88. The firm has a 50-day moving average price of $25.99 and a two-hundred day moving average price of $24.29. The company has a market capitalization of $1.23 billion, a P/E ratio of -25.10 and a beta of 1.92. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BLFS shares. Benchmark reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp lifted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Northland Securities raised their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, HC Wainwright decreased their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.43.

Read Our Latest Stock Report on BioLife Solutions

Hedge Funds Weigh In On BioLife Solutions

Hedge funds have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC acquired a new stake in BioLife Solutions during the third quarter worth about $57,000. GAMMA Investing LLC increased its holdings in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at approximately $122,000. Finally, Summit Global Investments bought a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $228,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

(Get Free Report)

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Articles